Skip to search formSkip to main contentSkip to account menu

CYC 202

Known as: CYC-202, CYC202 
National Institutes of Health

Related topics

Related topics

2 relations
Seliciclib

Broader (1)

roscovitine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
NPMc+ AML cell line shows differential protein expression and lower sensitivity to DNA-damaging and p53-inducing anticancer compounds
Nucleophosmin (NPM), an important regulator in p53 signaling pathway, is one of the most frequently mutated genes in acute… 
Highly Cited
2009
Highly Cited
2009
Seliciclib (CYC202, R‐roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model
We sought to determine whether seliciclib (CYC202, R‐roscovitine) could increase the antitumor effects of doxorubicin, with no… 
2008
2008
Metabolism of the Trisubstituted Purine Cyclin-Dependent Kinase Inhibitor Seliciclib (R-Roscovitine) in Vitro and in Vivo
Seliciclib (R-roscovitine, CYC202) is a small molecule inhibitor of cyclin-dependent kinases currently in phase II clinical… 
2007
2007
Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas
Despite recent improvements in treatment, a significant fraction of patients with diffuse large B-cell lymphoma (DLBCL) still… 
2006
2006
279 POSTER Pharmacodynamic effects of seliciclib (r-roscovitine, cyc202) in patients with undifferentiated nasopharyngeal cancer (NPC) using a window trial design
Highly Cited
2005
Highly Cited
2005
Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse.
R-roscovitine (seliciclib, CYC202) is a cyclin-dependent kinase inhibitor currently in phase II clinical trials in patients with… 
2005
2005
Phase I study of seliciclib (CYC202 or R-roscovitine) in combination with gemcitabine (gem)/cisplatin (cis) in patients with advanced non-small cell lung cancer (NSCLC).
2060 Background: Seliciclib (CYC202 or R-roscovitine) is a potent inhibitor of cyclin dependent kinases including CDK2/cyclin E… 
2005
2005
Pharmacodynamic effects of seliciclib (R-roscovitine, CYC202) in patients with undifferentiated nasopharyngeal carcinoma (NPC) using a window trial design.
2004
2004
Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis.
Determination of pharmacokinetic properties in the intact animal remains a major bottleneck in drug discovery. Cassette dosing… 
Review
2004
Review
2004
CYC-202 Cyclacel.
CYC-202, the lead compound from the CYC-200 series of small-molecule cyclin-dependent kinase inhibitors, is under development by… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)